Picture of Immuron logo

IMC — Immuron News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Australia's Immuron falls after stake acquisition in UK-based biotech firm

** Shares of biopharma co Immuron Ltd  IMC.AX  fall as much
as 2.5% to A$0.079
    ** Stock to mark worst session since Oct 3, if losses hold
    ** Co says signed subscription and option agreement with
UK-based gut health biotech co Ateria Health
    ** Deal to acquire an initial 17.5% stake in Ateria for
A$2.6 mln ($1.63 mln)
    ** Says deal for distribution of irritable bowel syndrome
treatment product JUVIA in Australian and North American
markets, among others 
    ** More than 125,000 shares change hands, compared with the
30-day average volume of about 45,000 
    ** Stock had fallen 19% this year, as of last close 
($1 = 1.5952 Australian dollars)
 (Reporting by Jaskiran Singh in Bengaluru)
 ((Jaskiran.Singh@thomsonreuters.com;))

Recent news on Immuron

See all news